Allergy Medications and Remedies: A Complete Guide for Grass, Mite, Dust, and Other Allergies

Allergic diseases represent one of the most prevalent chronic health conditions worldwide, affecting up to 30–40% of the global population. The pharmacological and non-pharmacological management of allergies has evolved dramatically over the past two decades, moving from purely symptomatic treatments to disease-modifying interventions that can fundamentally alter the natural history of allergic conditions.

The only definitive cure for allergies currently available is specific allergen immunotherapy (AIT), commonly known as the “allergy vaccine”, which works by re-educating the immune system to develop tolerance to specific allergens. However, AIT is not suitable for all patients, requires a long-term commitment (typically 3–5 years), and its efficacy varies depending on the allergen type and patient characteristics. For the vast majority of allergy sufferers, therefore, management relies on a combination of environmental allergen avoidance, pharmacological symptom control, and patient education.

The choice of allergy medications must be carefully individualized based on multiple factors:

• Severity of symptoms (mild, moderate, or severe)
• Duration and pattern (seasonal vs. perennial, intermittent vs. persistent)
• Patient’s overall health status (presence of comorbidities such as asthma, cardiovascular disease, or immunodeficiency)
• Age and physiological considerations (pregnancy, breastfeeding, pediatric vs. geriatric populations)
• Concomitant medications (potential drug interactions)
• Individual response and tolerance to specific drug classes

---

Diagnosis

Accurate diagnosis is the cornerstone of effective allergy management. Modern allergology employs a multi-layered diagnostic approach that begins with clinical history and progresses through increasingly specific investigations to identify the precise allergen triggers and characterize the immunological mechanism involved.

Medical History and Physical Examination

The diagnostic process begins with a comprehensive clinical interview conducted by an allergist or immunologist. This anamnesis aims to reconstruct the relationship between symptoms and potential allergen exposures, assess disease severity, and identify comorbid conditions.

Key elements of the clinical history:

• Symptom characterization: Nature, onset, duration, and severity of symptoms (rhinitis, conjunctivitis, asthma, urticaria, eczema, anaphylaxis)
• Temporal pattern: Seasonal vs. perennial symptoms, relationship to specific times of day, weather conditions, or activities
• Environmental triggers: Exposure to pollens, dust, pets, mold, occupational chemicals, foods, medications
• Personal and family atopic history: Previous allergic diseases, family history of asthma, rhinitis, eczema, or food allergy
• Lifestyle factors: Smoking status, dietary habits, home and work environments
• Previous treatments: Response to previous medications, including over-the-counter products
• Comorbidities: Asthma, cardiovascular disease, hypertension, glaucoma, thyroid disorders, immunodeficiency

The physical examination focuses on:

• Nasal mucosa: Pale, boggy, edematous appearance typical of allergic rhinitis; presence of nasal polyps
• Ocular findings: Conjunctival injection, chemosis, eyelid edema
• Skin: Signs of atopic dermatitis, urticaria, or contact dermatitis
• Chest: Wheezing, prolonged expiratory phase in asthma
• Vital signs: Particularly important in patients with severe asthma or anaphylaxis risk

Skin Prick Tests (SPT)

Skin prick testing remains the first-line diagnostic tool for IgE-mediated allergic diseases due to its rapidity, low cost, high sensitivity, and immediate results.

Procedure:

1. Standardized allergen extracts are applied as small drops on the volar forearm or upper back
2. A sterile lancet is used to gently prick the skin through each drop, introducing a minute quantity of allergen into the superficial dermis
3. Positive (histamine) and negative (saline) controls are applied simultaneously
4. Results are read after 15–20 minutes

Interpretation: A positive reaction is defined as a wheal (raised, firm papule) of ≥3 mm diameter greater than the negative control, surrounded by erythema. The size of the wheal correlates roughly with the degree of sensitization, though not necessarily with clinical severity.

Advantages:

• Immediate results (20 minutes)
• High sensitivity for most inhalant allergens
• Can test multiple allergens simultaneously
• Low cost
• Provides semi-quantitative information

Limitations:

• Requires discontinuation of antihistamines for 3–7 days before testing
• Cannot be performed on extensively eczematous skin
• May be suppressed by systemic corticosteroids
• Measures sensitization, not necessarily clinical relevance
• Risk of systemic reactions (rare but possible)
• Standardized extracts may not be available for all allergens

In Vitro Diagnostics (Specific IgE Testing)

When skin testing is contraindicated or impractical, serum-specific IgE testing (often called RAST, though this original method has been superseded) provides an alternative approach.

Methodology: Blood is drawn and analyzed using immunoassay platforms (e.g., ImmunoCAP, Immulite) that quantify allergen-specific IgE antibodies in kUA/L.

Advantages:

• Not affected by antihistamine use
• Can be performed regardless of skin condition
• No risk of systemic reactions
• Useful for patients who cannot discontinue medications
• Provides quantitative results that can be tracked over time

Limitations:

• Higher cost than SPT
• Results take hours to days
• Slightly lower sensitivity than SPT for some allergens
• Still measures sensitization, not clinical relevance
• Risk of false positives/negatives

Interpretation: Results are categorized into classes (0–6) based on IgE concentration. However, the correlation between IgE level and symptom severity is weak: a high IgE level does not necessarily mean severe symptoms, and vice versa. Results must always be interpreted in the clinical context.

Molecular Component-Resolved Diagnostics (CRD)

Component-resolved diagnostics represents the most advanced level of allergy testing, identifying IgE responses to specific, purified allergen proteins rather than whole extracts.

How it works: Using recombinant DNA technology, individual allergen proteins (components) are produced and used as targets for specific IgE measurement. For example, instead of testing for “grass pollen”, CRD can identify whether a patient is sensitized to Phl p 1, Phl p 5, or Phl p 12, each with different clinical implications.

Clinical applications:

1. Distinguish primary sensitization from cross-reactivity: For example, a patient positive to Bet v 1 (birch pollen) but negative to grass pollen components likely has cross-reactivity rather than true grass allergy
2. Predict clinical severity: Sensitization to certain components (e.g., Ara h 2 in peanut) correlates with higher anaphylaxis risk
3. Guide immunotherapy selection: Patients sensitized to major allergen components are better candidates for AIT
4. Identify patients at risk for systemic reactions: Particularly important for food allergies
5. Distinguish pollen-food syndrome from true food allergy: Based on cross-reactive component patterns

Limitations:

• Significantly higher cost than standard IgE testing
• Not all allergen components are commercially available
• Requires specialized interpretation

Provocation Tests

When history and specific IgE testing are inconclusive, or when it’s necessary to confirm clinical relevance, controlled provocation tests may be performed.

Types:

• Oral food challenge: The gold standard for diagnosing food allergy. Graduated doses of the suspected food are administered under medical supervision, with careful monitoring for objective symptoms.
• Nasal allergen challenge: Allergen is introduced directly into the nasal passages to assess rhinitis symptoms
• Bronchial allergen challenge: Used primarily in research settings for asthma
• Conjunctival challenge: Allergen applied to the conjunctiva

Safety considerations: Provocation tests carry a risk of triggering severe allergic reactions and must be performed only in hospital or specialized clinical settings with immediate access to resuscitation equipment and epinephrine. They are contraindicated in patients with a history of severe anaphylaxis to the allergen in question.

---

Treatment and Management

Modern allergy management follows a stepwise approach that begins with environmental control and patient education, adds pharmacological therapy as needed, and reserves immunotherapy for selected patients with persistent symptoms despite optimal conventional treatment.

First-Line Medications

Second-Generation Antihistamines

Second-generation (non-sedating) H1-antihistamines are the cornerstone of symptomatic treatment for allergic rhinitis, conjunctivitis, and urticaria. They work by competitively blocking H1 histamine receptors, preventing histamine from binding and triggering allergic symptoms.

Key examples and characteristics:

• Cetirizine (Zyrtec®): Potent, fast-acting, may cause mild drowsiness in a minority of patients
• Loratadine (Claritin®): Non-sedating, once-daily dosing, excellent safety profile
• Desloratadine (Aerius®): Active metabolite of loratadine, even less sedating
• Fexofenadine (Allegra®): Completely non-sedating, no cardiac effects
• Ebastine (Clever®): Rapid onset, effective for both nasal and ocular symptoms

Advantages:

• Rapid onset (30–60 minutes)
• Effective for sneezing, itching, rhinorrhea, and ocular symptoms
• Minimal sedation compared to first-generation agents
• Safe for long-term use
• Available over-the-counter in many countries

Limitations:

• Less effective for nasal congestion than intranasal corticosteroids
• Require regular dosing during exposure periods
• Do not treat underlying inflammation

Intranasal Corticosteroids

Intranasal corticosteroids are the most effective pharmacological treatment for persistent allergic rhinitis, addressing all nasal symptoms including congestion.

Key agents:

• Fluticasone propionate (Flonase®): High potency, minimal systemic absorption
• Mometasone furoate (Nasonex®): Excellent safety profile, approved for children as young as 2 years
• Budesonide (Rhinocort®): Systemic absorption <1%, suitable for long-term use
• Fluticasone furoate (Avamys®): Once-daily dosing, high patient satisfaction

Mechanism of action:

• Reduce eosinophilic and mast cell-mediated inflammation in nasal mucosa
• Decrease vascular permeability and mucosal edema
• Inhibit cytokine and chemokine production

Clinical benefits:

• Superior to antihistamines for nasal congestion
• Effective for all nasal symptoms (congestion, rhinorrhea, sneezing, itching)
• Also improve ocular symptoms (though less than ocular antihistamines)
• Prevent progression from rhinitis to asthma in children

Administration tips:

• Require daily regular use for optimal effect (not on-demand)
• Onset of action: 6–12 hours for initial effect, maximal benefit after 1–2 weeks
• Proper technique is crucial (head tilted forward, spray directed laterally)
• Minimal systemic absorption (<1%) means negligible systemic side effects

Ocular Preparations

For prominent allergic conjunctivitis symptoms:

Antihistamine eye drops:

• Ketotifen (Zaditor®): Dual-action antihistamine and mast cell stabilizer
• Olopatadine (Patanol®): Highly effective, twice-daily dosing
• Azelastine (Optivar®): Rapid onset, good tolerability

Mast cell stabilizers:

• Sodium cromoglicate (Cromolyn®): Excellent safety, requires prophylactic use (2–4 times daily)
• Lodoxamide (Alomide®): More potent than cromolyn, suitable for children

Decongestant eye drops:

• Naphazoline/pheniramine combinations: Rapid relief but limited to short-term use (<7 days) due to rebound hyperemia risk

Nasal Decongestants

Topical nasal decongestants provide rapid relief of nasal congestion through vasoconstriction but carry significant risks:

Agents:

• Xylometazoline (Otrivin®)
• Oxymetazoline (Afrin®)

Critical limitation:

• Use must be limited to maximum 3–5 days to avoid rhinitis medicamentosa (rebound congestion)
• Risk of tachyphylaxis and dependency
• Contraindicated in hypertension, glaucoma, hyperthyroidism, and urinary retention

Leukotriene Receptor Antagonists

Montelukast (Singulair®) is particularly useful for patients with both allergic rhinitis and asthma:

• Blocks cysteinyl leukotriene receptors (CysLT1)
• Reduces both nasal and bronchial inflammation
• Effective for exercise-induced bronchoconstriction
• Once-daily oral dosing

Important safety note: The FDA has issued a boxed warning regarding neuropsychiatric side effects (mood changes, sleep disturbances, suicidal ideation), so patients should be monitored for these symptoms.

Topical Treatments for Skin Allergies

For allergic contact dermatitis and eczema:

• Topical corticosteroids: Various potencies for different body sites and severity
• Calcineurin inhibitors (tacrolimus, pimecrolimus): Steroid-sparing agents for sensitive areas
• Barrier creams: Prevent allergen penetration

For urticaria:

• First-line: Second-generation antihistamines (dose may be increased up to 4x standard dose in chronic urticaria)
• Second-line: Omalizumab (anti-IgE monoclonal antibody) for chronic spontaneous urticaria refractory to antihistamines

Desensitizing Immunotherapy

Allergen immunotherapy (AIT) is the only disease-modifying treatment for IgE-mediated allergies. It involves administering gradually increasing doses of allergen to induce immunological tolerance.

Mechanisms of action:

• Induction of allergen-specific regulatory T cells (Tregs)
• Shift from Th2 to Th1/Treg immune response
• Production of IgG4 “blocking antibodies”
• Reduction of mast cell and basophil reactivity

Routes of administration:

• Subcutaneous immunotherapy (SCIT): Traditional injection-based therapy
• Sublingual immunotherapy (SLIT): Tablets or drops administered daily at home

Indications:

• Moderate-to-severe allergic rhinitis inadequately controlled by medications
• Allergic asthma (mild-to-moderate, stable)
• Venom allergy (hymenoptera)
• Selected cases of food allergy (under investigation)

Duration: 3–5 years for durable, post-treatment benefit

Efficacy:

• 60–80% of well-selected patients achieve clinically significant improvement
• Reduces symptom scores and medication needs
• May prevent progression from rhinitis to asthma in children
• Effects persist for years after discontinuation

Safety:

• SCIT: Risk of systemic reactions (1 per 1,000 injections); requires medical supervision
• SLIT: Very rare systemic reactions; mainly local oral symptoms

Emergency Management

Anaphylaxis protocol:

1. Immediate intramuscular epinephrine into the lateral thigh (0.3–0.5 mg for adults, 0.01 mg/kg for children)
2. Call emergency services immediately
3. Supine position with legs elevated
4. Second dose if no improvement after 5–15 minutes
5. Hospital observation for 4–6 hours minimum (risk of biphasic reaction)

All patients at risk must carry two epinephrine auto-injectors and know how to use them.

Adjunctive emergency treatments:

• Antihistamines: For cutaneous symptoms (do not treat anaphylaxis)
• Corticosteroids: May reduce risk of biphasic reaction (delayed effect)
• Bronchodilators: For bronchospasm
• Oxygen: For hypoxemia
• IV fluids: For hypotension

Lifestyle and Environmental Prevention

Nasal irrigation:

• Daily saline or hypertonic saline nasal washes
• Removes allergens, mucus, and inflammatory mediators
• Improves mucociliary clearance
• Enhances intranasal medication delivery

Air purification:

• HEPA filters remove >99.97% of airborne particles ≥0.3 μm
• Particularly effective for dust mite, pet dander, and mold allergens
• Place in bedroom and main living areas
• Maintain filters regularly

Environmental control for specific allergens:

• Dust mites: Encase mattresses/pillows, wash bedding weekly at 60°C, humidity <50%
• Pollen: Monitor pollen counts, keep windows closed during high counts, shower after outdoor exposure
• Pets: Keep out of bedroom, HEPA filtration, regular bathing (dogs)
• Mold: Dehumidifiers, fix leaks promptly, remove visible mold

Pollen monitoring:

• Check daily pollen forecasts (available through weather services and allergy apps)
• Plan outdoor activities during low pollen periods
• Start preventive medications 1–2 weeks before anticipated pollen season

---

Sources and Bibliography

• Mayo Clinic – Allergy medications: Know your options
• Allergy UK – Types of Allergy and Treatments
• Bousquet, J., Khaltaev, N., Cruz, A.A., et al. (2008). “Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update”. Allergy, 63(Suppl 86), 8–160.
• Canonica, G.W., Bousquet, J., Mullol, J., Scadding, G.K., & Virchow, J.C. (2007). “A survey of the burden of allergic rhinitis in Europe”. Allergy, 62(Suppl 85), 17–25.
• Scadding, G.K., Durham, S.R., Mirakian, R., et al. (2008). “BSACI guidelines for the management of allergic and non-allergic rhinitis”. Clinical and Experimental Allergy, 38(1), 19–42.
• Seidman, M.D., Gurgel, R.K., Lin, S.Y., et al. (2015). “Clinical practice guideline: Allergic rhinitis”. Otolaryngology–Head and Neck Surgery, 152(1S), S1–S43.
• Dykewicz, M.S., & Hamilos, D.L. (2010). “Rhinitis and sinusitis”. Journal of Allergy and Clinical Immunology, 125(2 Suppl 2), S103–S115.
• Brożek, J.L., Bousquet, J., Agache, I., et al. (2017). “Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2016 revision”. Journal of Allergy and Clinical Immunology, 140(4), 950–958.
• Matricardi, P.M., Kleine-Tebbe, J., Hoffmann, H.J., et al. (2016). EAACI Molecular Allergology User’s Guide. European Academy of Allergy and Clinical Immunology.
• Simons, F.E.R., Ardusso, L.R., Bilò, M.B., et al. (2011). “World Allergy Organization anaphylaxis guidelines: Summary”. Journal of Allergy and Clinical Immunology, 127(3), 587–593.e1-22.
• Muraro, A., Roberts, G., Worm, M., et al. (2014). “Anaphylaxis: Guidelines from the European Academy of Allergy and Clinical Immunology”. Allergy, 69(8), 1026–1045.
• Golden, D.B.K., Demain, J., Freeman, T., et al. (2017). “Stinging insect hypersensitivity: A practice parameter update 2017”. Annals of Allergy, Asthma & Immunology, 119(4), 343–354.
• Cox, L., Nelson, H., Lockey, R., et al. (2011). “Allergen immunotherapy: A practice parameter third update”. Journal of Allergy and Clinical Immunology, 127(1 Suppl), S1–S55.
• Demoly, P., Calderón, M.A., Casale, T.B., et al. (2020). “Assessment of disease control in allergic rhinitis”. Clinical and Translational Allergy, 10, 38.
• Bousquet, P.J., Combescure, C., Neukirch, F., et al. (2009). “Visual analog scales can assess the severity of rhinitis”. Allergy, 64(4), 519–524.